Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

NCT01181258 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: Rituximab
BIOLOGICAL: Interleukin-2
BIOLOGICAL: Natural killer cells
DRUG: Cyclophosphamide
DRUG: Methylprednisolone
DRUG: Fludarabine

Sponsor

Masonic Cancer Center, University of Minnesota